

Marianne Klemp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6955740/publications.pdf>

Version: 2024-02-01

50
papers

2,974
citations

257450

24
h-index

254184

43
g-index

51
all docs

51
docs citations

51
times ranked

3882
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinson's disease, treatment choice and survival over time. <i>Clinical Parkinsonism & Related Disorders</i> , 2022, 6, 100136.	0.9	0
2	Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors. <i>Parkinson's Disease</i> , 2021, 2021, 1-7.	1.1	2
3	Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1731-1743.	1.9	28
4	Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review. <i>BMJ Open</i> , 2020, 10, e036412.	1.9	6
5	Critical appraisal of adverse effects reporting in the "Treatment for Adolescents With Depression Study (TADS)". <i>BMJ Open</i> , 2019, 9, e026089.	1.9	6
6	Characterization of gastrointestinal adverse effects reported in clinical studies of corticosteroid therapy. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 19-26.	5.0	2
7	A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 88-105.	1.2	33
8	A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1917-1927.	2.4	54
9	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. <i>BMJ Open</i> , 2017, 7, e014880.	1.9	18
10	More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 104-116.	1.2	49
11	Eunetha Tools and Methods "Facilitating Uptake by Training Activities. <i>Value in Health</i> , 2015, 18, A561.	0.3	0
12	Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. <i>PLoS ONE</i> , 2015, 10, e0137258.	2.5	15
13	Responsibility and accountability for well informed health-care decisions: a global challenge. <i>Lancet, The</i> , 2015, 386, 826-828.	13.7	4
14	TRANSCATHETER AORTIC VALVE IMPLANTATION AND ADAPTIVE / PROGRESSIVE COVERAGE. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 250-251.	0.5	0
15	Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. <i>BMJ Open</i> , 2014, 4, e004587.	1.9	215
16	ENDPOINTS FOR RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 508-513.	0.5	11
17	Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010. <i>Pharmacoeconomics</i> , 2014, 32, 367-375.	3.3	134
18	Expansion of the Norwegian HPV Vaccination Program. <i>Value in Health</i> , 2014, 17, A636.	0.3	0

#	ARTICLE	IF	CITATIONS
19	HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health, 2014, 14, 867.	2.9	23
20	Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation. Pharmacoeconomics, 2014, 32, 601-612.	3.3	43
21	Are Both Antidepressant Drug Effects and Test Scores Unspecific?. Journal of Pharmacological & Biomedical Analysis, 2014, 02, .	0.6	0
22	NEW ANTICOAGULANTS AS THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT. International Journal of Technology Assessment in Health Care, 2013, 29, 234-243.	0.5	12
23	Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open, 2012, 2, e000653.	1.9	146
24	Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. Journal of Public Health, 2012, 34, 539-547.	1.8	13
25	INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY. International Journal of Technology Assessment in Health Care, 2012, 28, 374-381.	0.5	20
26	Meta-Regression Analysis of Paroxetine Clinical Trial Data. Journal of Clinical Psychopharmacology, 2011, 31, 201-206.	1.4	6
27	HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecologic Oncology, 2011, 120, 430-438.	1.4	88
28	Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. International Journal of Cancer, 2011, 128, 1120-1128.	5.1	156
29	Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. International Journal of Technology Assessment in Health Care, 2011, 27, 253-260.	0.5	45
30	A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo. Journal of Clinical Psychopharmacology, 2011, 31, 698-704.	1.4	29
31	What principles should govern the use of managed entry agreements?. International Journal of Technology Assessment in Health Care, 2011, 27, 77-83.	0.5	123
32	Health technology assessment to optimize health technology utilization: Using implementation initiatives and monitoring processes. International Journal of Technology Assessment in Health Care, 2010, 26, 309-316.	0.5	37
33	Do Various Glitazones Have the Same Risk of Acute Myocardial Infarction? Indirect Evidence from a Population-Based Norwegian Cohort Study. The Open Diabetes Journal, 2009, 2, 62-68.	0.4	1
34	Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Pharmacoepidemiology and Drug Safety, 2008, 17, 707-713.	1.9	14
35	Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2006, 55, 1553-1564.	4.2	220
36	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. British Journal of Cancer, 2006, 95, 1474-1482.	6.4	260

#	ARTICLE	IF	CITATIONS
37	A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2580-2580.	1.6	4
38	HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. <i>Journal of Molecular Medicine</i> , 2003, 81, 43-50.	3.9	26
39	A TGF β 2RII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 469-476.	4.2	67
40	Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. <i>Experimental Dermatology</i> , 2001, 10, 161-167.	2.9	41
41	Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. <i>International Journal of Cancer</i> , 2001, 92, 441-450.	5.1	261
42	Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13255-13260.	7.1	233
43	Combination of GM-CSF with antitumour vaccine strategies. <i>European Journal of Cancer</i> , 1999, 35, S33-S35.	2.8	10
44	Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer. <i>Vox Sanguinis</i> , 1998, 74, 489-495.	1.5	32
45	Generation and characterization of GP-100 peptide-specific NK-T cell clones. , 1998, 75, 794-803.		11
46	Mutant ras peptide vaccines. <i>European Journal of Cancer</i> , 1997, 33, S289.	2.8	1
47	Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. , 1997, 72, 784-790.		147
48	Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. <i>British Journal of Cancer</i> , 1996, 74, 1828-1833.	6.4	29
49	Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study. , 1996, 65, 450-453.		97
50	Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. <i>Lancet, The</i> , 1995, 346, 1399-1400.	13.7	200